This is the first study to date to investigate NITR supplementation as a potential therapy for DMD, and we show that the metabolic perturbations in dystrophin-deficient skeletal muscle could not be overcome by enhancing nNOS-independent NO production. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.